Product Details

Sublocade

Buprenorphine
100 mg/0.5 mL
Solution for Injection
0.5-mL Prefilled Syringe

DIN/PIN/NPN

02483084

Manufacturer

Indivior UK Limited

Formulary Listing Date

2020-04-30  

Unit Price

550.0000

Amount MOH Pays

550.0000

Coverage Status

Limited Use Product

ODB Formulary Therapeutic Classification

Therapeutic Note

NO

ATC Code

N07BC01

Interchangeable Products

NO  

LU Clinical Criteria

LU Code Auth. Period Clinical Criteria
577 1 year

For the management of moderate to severe opioid use disorder as a part of a complete treatment plan that includes counselling and psychosocial support in adult patients who meet the following criteria:

- The patient has been induced and is stabilized on an equivalent of 8mg to 24mg per day of transmucosal buprenorphine for a minimum of seven days; AND
- The patient is under the care of a health care provider with experience in the diagnosis and management of opioid use disorder; AND
- Each dose is administered subcutaneously in the abdominal region by a certified healthcare provider who has received instruction and training.

Recommended dose: 300mg/month for two months, followed by a maintenance dose of 100mg/month. Maintenance dose may be increased to 300mg/month only if patient does not demonstrate satisfactory clinical response.

Note: In clinical trials, the 300mg/month maintenance dose did not provide additional efficacy as compared to the 100mg/month dose and was associated with a higher incidence of adverse events and study discontinuations. A minimum of 26 days is required between consecutive doses

 

EAP Criteria

NO

Product Monograph

View Monograph